Steven E. Kahn
0000-0001-7307-9002
Publication & Citation Trends
Publications
0 total
Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: A secondary analysis of the SELECT trial
Cited by 3
Semantic Scholar
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
Cited by 33
Semantic Scholar
EFFECT OF THE GLP-1 RECEPTOR AGONIST SEMAGLUTIDE ON TOTAL CARDIOVASCULAR EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASE AND OVERWEIGHT OR OBESITY BUT NO DIABETES IN THE SELECT TRIAL
Cited by 1
Semantic Scholar
Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the select trial
Cited by 2
Semantic Scholar
Effect of Semaglutide on Kidney Outcomes in People With Overweight or Obesity and Established Cardiovascular Disease in the SELECT Trial
Cited by 1
Semantic Scholar
Semaglutide improves cardiovascular outcomes in patients with high risk for metabolic dysfunction-associated steatohepatitis – a subgroup analysis from the SELECT trial
Cited by 3
Semantic Scholar
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Cited by 171
Semantic Scholar
Research Topics
Pancreatic function and diabetes
(208)
Diabetes Treatment and Management
(198)
Metabolism, Diabetes, and Cancer
(172)
Diabetes Management and Research
(159)
Diabetes, Cardiovascular Risks, and Lipoproteins
(147)
Affiliations
Kagoshima University
Dartmouth College
University of Geneva
University of Southern California
University of Iowa